September 2012, Vol 1, No 4 - Conference News
More than 80% of patients with relapsed or refractory multiple myeloma responded to a monoclonal antibody against a cell surface protein expressed by almost all myeloma cells, results of a phase 2 clinical trial showed. All patients received lenalidomide and dexamethasone and were randomized to 10 or 20 mg of [ Read More ]
September 2012, Vol 1, No 4 - Conference News
A drug that targets a previously overlooked mutation led to objective responses in 8 of 14 patients with advanced non–small cell lung cancer (NSCLC), according to results of a proof-of-principle study. Some patients had symptomatic relief within days of beginning treatment with crizotinib, Alice T. Shaw, MD, PhD, reported at [ Read More ]
Copyright 2023. Amplity Medical Communications. All Rights Reserved. Privacy Policy. Sitemap.
